Rating Rationale
February 25, 2020 | Mumbai
Shri Ram Krupa Medicare Private Limited
Long-term rating upgraded to 'CRISIL BB+/Stable'
 
Rating Action
Total Bank Loan Facilities Rated Rs.46 Crore (Enhanced from Rs.40 Crore)
Long Term Rating CRISIL BB+/Stable (Upgraded from 'CRISIL BB/Stable')
Short Term Rating CRISIL A4+ (Assigned)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has upgraded its rating on the long-term bank facilities of Shri Ram Krupa Medicare Private Limited (SRKMPL) to 'CRISIL BB+/Stable' from 'CRISIL BB/Stable' and has assigned its 'CRISIL A4+' rating to the short-term bank facility.
 
The upgrade reflects CRISIL's belief that SRKMPL shall sustainably maintain its improved financial risk profile, particularly liquidity, supported by improved cash accruals. Topline rose 37% to Rs 81.6 crore in fiscal 2019, and is expected to grow 20% annually over the medium term, backed by ramp up and stabilisation of operations at the new hospital, Tricolour Super Multi-Speciality Hospital (Tricolour), and better absorption of overheads. This will translate into increase in annual accrual to Rs 10-12 crore from Rs 5.65 crore in fiscal 2019. The rating action also factors in absence of any large capital expenditure (capex).
 
The rating continues to reflect the company's established position in healthcare services, supported by the extensive experience of the promoters, and its moderate financial risk profile. These strengths are partially offset by occupancy risk at Tricolour and geographical concentration in revenue.

Analytical Approach

Unsecured loan of Rs 4.65 crore extended to the company by the promoters has been treated as neither debt nor equity because the loan is expected to remain in the business over the medium term.

Key Rating Drivers & Detailed Description
Strengths: 
* Established position in healthcare services, supported by the extensive experience of the promoters
The company has a track record of 17 years in cardiac care, with experienced promoters and management team, and association with reputed doctors. The company manages cardiac hospitals under Baroda Heart Institute & Research Centre at Vadodara and Bharuch in Gujarat. Its new hospital, Tricolour, at Vadodara commenced operations in fiscal 2018. Based on specialised services in cardiology, similar services are being provided to other hospitals in Jamnagar and Bhavnagar as well.
 
* Moderate financial risk profile
Networth declined to Rs 42.63 crore as on March 31, 2019, from Rs 51.7 crore because of losses (driven by high depreciation) in fiscals 2018 and 2019. Gearing was comfortable at 0.95 time as on March 31, 2019. Gearing is expected to improve going forward backed by gradual rise in networth levels due to consistent profitability along with decline in term debt due to regular repayment of term loans. Due to stretched payables, total outside liabilities to adjusted networth ratio was at 1.53 time. Interest coverage was 2.5 times during fiscal 2019.
 
Weaknesses:
* Occupancy risk at Tricolour
Though the occupancy level at Tricolour increased from 7% in fiscal 2018 to 21% in fiscal 2019, it remains low. Nevertheless, with stabilisation of operations, the hospital will witness increase in occupancy. The regular repayment of term loan (raised for setting up Tricolour) depends on additional cash flow from the hospital. Hence, occupancy will remain a key rating monitorable.
 
* Geographical concentration in revenue
The company operates three owned hospitals (two in Vadodara and one in Bharuch) and provides services in two other hospitals (one each in Bhavnagar and Jamnagar). Revenue is concentrated in Gujarat, and intensifying competition or changing dynamics and regulations in the state may limit growth in operations and earnings.
Liquidity Adequate

Liquidity will remain adequate backed by increase in net cash accrual after stabilisation of operations at Tricolour. Cash accrual is expected to rise to Rs 10-12 crore per annum over the two fiscals through 2021 against yearly debt obligation of Rs 5.8 crore. Fund-based limit of Rs 8 crore was utilised 67% on average over the 12 months through November 2019.

Outlook: Stable

CRISIL believes SRKMPL will continue to benefit from its established presence in the healthcare services industry and the strong technical expertise of its promoters.
 
Rating sensitivity factors
Upward Factors
* Increase in cushion between net cash accrual and yearly debt obligation above Rs 5 crore
* Sustained rise in occupancy at Tricolour
 
Downward Factors
* Decline in net cash accrual below Rs 7 crore
* Large capex impacting financial risk profile and liquidity

About the Company

Incorporated in November 1999, SRKMPL provides healthcare services, primarily cardiology, in Vadodara, Bharuch, Jamnagar, and Bhavnagar through Baroda Heart Institute & Research Centre. Dr Mahesh Basarge, Dr Parvinder Singh, and Mr Janak Patel are the directors of the company. It is has set up a 118-bed super multispecialty hospital in Vadodara, which started commercial operations in fiscal 2018. It received private equity funding of Rs 32.4 crore in fiscal 2014 from Baswood Holding Ltd. Its registered office is in Vadodara.

Key Financial Indicators
Particulars Unit 2019 2018
Revenue Rs crore 81.63 61.93
Profit after tax (PAT) Rs crore -3.75 -4.66
PAT margin % -4.59 -6.88
Adjusted debt/adjusted networth Times 0.95 0.93
Interest coverage Times 2.52 1.77
Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon rate (%) Maturity date Issue size (Rs crore) Rating assigned with outlook
NA Cash Credit NA NA NA 8 CRISIL BB+/Stable
NA Term Loan NA NA Dec-2024 36.5 CRISIL BB+/Stable
NA Bank Guarantee NA NA NA 1.5 CRISIL A4+
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  44.50  CRISIL BB+/Stable      15-01-19  CRISIL BB/Stable      31-07-17  CRISIL BB+/Stable  CRISIL BB+/Stable 
Non Fund-based Bank Facilities  LT/ST  1.50  CRISIL A4+    --    --    --    --  -- 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 1.5 CRISIL A4+ Cash Credit 4 CRISIL BB/Stable
Cash Credit 8 CRISIL BB+/Stable Term Loan 36 CRISIL BB/Stable
Term Loan 36.5 CRISIL BB+/Stable -- 0 --
Total 46 -- Total 40 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Neha Sharma
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 79 4024 4509
neha.sharma@crisil.com


Ronak Vijayvargiya
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 79 4024 4527
Ronak.Vijayvargiya@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL